Total T lymphocytes in primary bronchial carcinoma.

Roberts, Helene; Donohoe, W. T. A.; Hewitt, S; Da, Evans

doi:10.1136/thx.32.1.84

Cited by 9 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies on T lymphocytes in lung cancer and in smoking have pro duced conflicting results showing T cells as either increased or unchanged [3,4,[21][22][23][24]. We found the percentage of OKT3+ cells increased in the deep lung but not in blood, of patients with pulmon ary neoplasia who were heavy and moder ate smokers, in respect to controls (light smokers).…”

Section: Discussionsupporting

confidence: 36%

Determination of T Lymphocyte Subpopulations in Patients with Lung Cancer

et al. 1987

View full text Add to dashboard Cite

In order to determine whether the alterations of immunoregulatory T cells described both in smokers and in patients with lung cancer occur in the deep lung as well as in peripheral blood, we analyzed T lymphocyte subpopulations in bronchoalveolar lavage (BAL) and in the blood of 12 patients with untreated lung cancer and of 8 controls. The immunocompetent cellular population of BAL fluid analyzed by differential cell count of alveolar macrophages, lymphocytes and neutrophils did not show considerable differences in the two groups studied. By contrast, the analysis of BAL T lymphocytes and their subsets showed significant alterations in patients compared with controls: a percentage increase of OKT3⁺ and OKT8⁺ lymphocytes and a decrease of the OKT4⁺/OKT8⁺ ratio was found in both the involved and uninvolved lung of patients. The immunologic pattern of T lymphocytes in blood did not show significant differences between patients and controls. Our data indicate that alterations in immunoregulatory T cells in lung cancer are more pronounced in BAL fluid obtained from both lungs than in peripheral blood.

show abstract

Section: Discussionsupporting

confidence: 36%

Determination of T Lymphocyte Subpopulations in Patients with Lung Cancer

et al. 1987

View full text Add to dashboard Cite

show abstract

“…There are many reports that patients with lung cancer often display immune abnormalities, 1 – 10 , 13 , 14 , 18 ) and these abnormalities in cell mediated immunity have been considered to be significant in the development and progression of lung cancer 1 , 4 , 9 , 15 , 16 , 20 , 21 , 23 ) .…”

Section: Discussionmentioning

confidence: 99%

“…Evaluation of immunocompetence in patients with lung cancer by peripheral total lymphocyte counts, 1 , 4 , 8 – 10 ) percentage of lymohocytes, 3 ) delayed skin hypersensitivity test, 6 , 10 , 20 , 21 , 23 ) quantitation of peripheral lymphocyte subsets 4 , 5 , 7 , 9 , 10 , 12 ) and mitogen stimulation of lymphocytes 2 , 8 ) has demonstrated both functional and quantitative abnormalities.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Changes of Peripheral T Lymphocyte Subsets Following Treatment in Patients with Bronchogenic Carcinoma

Kim

1989

Korean J Intern Med

View full text Add to dashboard Cite

We evaluated the changes of peripheral leukocyte counts, lymphocyte counts, and percentage of lymphocytes and T cell subsets (OKT4(%), OKT8(%) and OKT4/OKT8) in 49 untreated lung cancer patients of whom 23 were followed up after therapy (8 pulmonary resection, 15 chemotherapy). Total WBC counts were significantly increased in stage I or II compared to controls and were decreased after operation.Total counts and percentage of lymphocytes were decreased (esp. stage III NSCLC, SCLC esp. ED, squamous) and were persistently decreased after treatment in nonresponders. OKT8(%) was decreased (esp. SCLC, squamous, adenocarcinoma, all stages of NSCLC, and ED of SCLC) and was persistently decreased in stage III after treatment.The OKT4/OKT8 ratio was increased (esp. adenocarcinoma and stage III NSCLC) and returned to the normal range after treatment.In nonresponders, total lymphocyte counts were decreased before treatment compared to responders and persistently decreased before and after treatment compared to controls, and OKT8(%) was persistently decreased after treatment compared to controls.In conclusion, immunoabnormalities in patients with lung cancer might be improved following treatment.

show abstract

“…Regarding the number of lymphocytes and T cells in tumourbearing patients, there is much confusion in the literature. Some investigators report normal ranges of T lymphocytes (Wybran & Fudenberg, 1976;Middlekoop et al, 1976) whereas others find decreased numbers (Dellon et al, 1975;Roberts et al, 1977) mostly depending on technical variables. The suppression of neutrophil function in carcinoma patients, described by Bauim (I1975), was not confirmed in this study.…”

Section: Discussionmentioning

confidence: 99%

Harmful effects of i.v. Corynebacterium Parvum given at the same time as cyclophosphamide in patients with squamous-cell carcinoma of the bronchus

Blomberg¹,

Glerum²,

Croles³

et al. 1980

Br J Cancer

View full text Add to dashboard Cite

Summary.-The effects are reported of a combination therapy of i.v. C. parvum and cyclophosphamide on the survival time and immune responses of patients with inoperable squamous-cell carcinoma of the bronchus. The immune status of the patients was evaluated by determining the antibody response to C. parvum, the E and EAC rosettes, the PHA response of blood lymphocytes, the skin-test reactivity to Candida and PPD, the response to DNCB and the chemotaxis and NBT-dye reduction capacity of neutrophil leucocytes.The survival time of patients treated with the combination therapy was found to be significantly shorter than that of untreated patients and of those receiving cyclophosphamide only. Severe side effects were observed after C. parvum infusions, with no decrease on repeated administration. The effect of C. parvum on the different immune parameters of cyclophosphamide-treated patients was negligible, though there was a normal antibody response to C. parvum.

show abstract

Total T lymphocytes in primary bronchial carcinoma.

Cited by 9 publications

References 12 publications

Determination of T Lymphocyte Subpopulations in Patients with Lung Cancer

Determination of T Lymphocyte Subpopulations in Patients with Lung Cancer

Changes of Peripheral T Lymphocyte Subsets Following Treatment in Patients with Bronchogenic Carcinoma

Harmful effects of i.v. Corynebacterium Parvum given at the same time as cyclophosphamide in patients with squamous-cell carcinoma of the bronchus

Contact Info

Product

Resources

About